Testing of unique 3D-printed pancreatic tissues to confirm appropriate insulin-releasing function for the regulation of blood glucose in diabetes

测试独特的 3D 打印胰腺组织，以确认调节糖尿病血糖的适当胰岛素释放功能

• 批准号: 536342-2018
• 负责人: Kieffer, Timothy
• 金额: $ 0.91万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Engage Plus Grants Program
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=655514
• 关键词: Testing; unique; 3D; printed; pancreatic

Insulin replacement by implant of differentiated stem cells is a promising approach to treat diabetes, and is now**being tested clinically, including here in Vancouver. Initial findings from the clinical testing indicate that**improvements are required to improve graft vascularization, survival and function. Vancouver-based Aspect**Biosystems Ltd has developed cell bioprinting technology that may be able to address these limitations. Thus,**the goal of this project is to assess the survival and function of novel bioprinted 3D tissue containing human**embryonic stem cells (hESCs) differentiated toward insulin-producing cells. This work will expand on the first**phase of the project, previously funded by the NSERC Engage program, in which we collaborated with Aspect**to assess and optimize the viability of undifferentiated hESCs in bioprinted tissue. Based upon our progress, we**can now optimize the 3D pancreas tissue to determine which composition best supports cell viability and**function of differentiated hESCs. In vitro function of bioprinted cells will be assessed by measuring insulin**secretion in response to nutrients and beta cell secretagogues in a dynamic perifusion apparatus. Further testing**will be conducted in immunodeficient, diabetic rats to determine whether the bioprinted tissue is able to**reverse diabetes and restore control of glucose regulation. The Kieffer lab will provide Aspect with human ES**cells that have been differentiated toward insulin-producing cells. These cells will be bioprinted by Aspect into**living biocompatible 3D structures using Aspect's unique alginate/collagen bioink. The project will provide an**excellent training opportunity for students in cutting edge biomedical engineering at the interface of academia**and industry, and could lead to substantial investments in follow-up research and development.

通过植入分化干细胞来替代胰岛素是治疗糖尿病的一种有前景的方法，目前**正在进行临床测试，包括在温哥华。临床测试的初步结果表明，需要进行改进才能改善移植物血管化、存活和功能。总部位于温哥华的 Aspect**Biosystems Ltd 开发了细胞生物打印技术，或许能够解决这些限制。因此，**该项目的目标是评估含有分化为胰岛素产生细胞的人类**胚胎干细胞 (hESC) 的新型生物打印 3D 组织的存活和功能。这项工作将扩展该项目的第一阶段，该项目之前由 NSERC Engage 计划资助，我们与 Aspect** 合作评估和优化生物打印组织中未分化 hESC 的活力。根据我们的进展，我们现在可以优化 3D 胰腺组织，以确定哪种组合物最能支持分化 hESC 的细胞活力和功能。生物打印细胞的体外功能将通过测量动态灌注装置中营养物和β细胞促分泌剂响应的胰岛素**分泌来评估。进一步的测试**将在免疫缺陷的糖尿病大鼠中进行，以确定生物打印组织是否能够**逆转糖尿病并恢复血糖调节的控制。 Kieffer 实验室将为 Aspect 提供人类 ES** 细胞，这些细胞已分化为胰岛素生成细胞。 Aspect 将使用 Aspect 独特的藻酸盐/胶原生物墨水将这些细胞生物打印成**活的生物相容性 3D 结构。该项目将为学生在学术界**和工业界的前沿生物医学工程领域提供绝佳的培训机会，并可能为后续研究和开发带来大量投资。